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niﬁcantly improved outcome in patients with KRAS wild-type metastatic colorectal cancer.
Quality of life (QoL) was assessed, and associations with tumour response and survival were
investigated.
Patients and methods: The European Organization for Research and Treatment of Cancer
QoL questionnaire-core 30 was used, focusing on global health status (GHS)/QoL and social
functioning scales. Radiological response was assessed by an independent review committee.
Results: QoL was evaluable in 627/666 patients (94%) with KRAS wild-type tumours; of these
52% received FOLFIRI, and 48% FOLFIRI plus cetuximab. Pattern mixture analysis revealed
no signiﬁcant differences for GHS/QoL (P = 0.12) and social functioning scores (P = 0.43)
between the treatment arms. In additional analyses: early skin reactions in patients receiving
cetuximab did not signiﬁcantly affect these QoL scales, and tumour response was more com-
mon (58% versus 40%, P = 0.0002) and survival longer (Hazard ratio 1.68, P < 0.0001) in23
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440 I. La´ng et al. / European Journal of Cancer 49 (2013) 439–448asymptomatic compared with symptomatic patients at baseline. Adding cetuximab to FOLF-
IRI was associated with signiﬁcantly higher tumour response irrespective of patient baseline
symptomatic status, and enhanced symptom relief from baseline in those whose tumours
had responded.
Conclusion: Adding cetuximab to FOLFIRI improved response rate and survival without
either improving or negatively impacting on GHS/QoL and social functioning.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
In the CRYSTAL study, adding cetuximab to ﬁrst-
line irinotecan and infusional ﬂuorouracil and leucovo-
rin (FOLFIRI) signiﬁcantly improved survival (hazard
ratio [HR] 0.796, P = 0.0093), progression-free survival
(PFS, HR 0.696, P = 0.0012) and tumour response
(odds ratio 2.069, P < 0.001) compared with chemother-
apy alone in patients with KRAS wild-type metastatic
colorectal cancer (mCRC).1 Whilst the reduction of
mortality and morbidity remains one of the most impor-
tant goals in oncology research, therapies should ideally
also lead to improvements in general health status and
quality of life (QoL).
The main and most important reported side-eﬀects
associated with the combination of cetuximab with
ﬁrst-line chemotherapy regimens in mCRC are an
increase in skin reactions and infusion-related reactions
during ﬁrst administration.1–4
In pretreated patients with KRAS wild-type mCRC,
signiﬁcant improvements in both clinical outcome and
QoL scores were reported when cetuximab was com-
bined with irinotecan or best supportive care compared
with these therapies alone.5–7 Associations between eﬃ-
cacy and QoL were reported in the CO.17 study in this
setting, where patients with objective tumour response
or disease control were signiﬁcantly more likely to gain
improvements in QoL scores compared with patients
with progressive disease.6
A number of studies have investigated associations
between QoL and clinical outcome and have reported
that patient QoL scores at baseline may be an indepen-
dent predictor of survival in several diﬀerent cancer
types including mCRC.8–12
Patient QoL assessment was a secondary objective in
the CRYSTAL study. The present investigation reports
an analysis of QoL data collected in CRYSTAL study
patients with KRAS wild-type tumours.12. Patients and methods
2.1. Study design, treatment and objectives
The CRYSTAL study (NCT00154102) design, patient
eligibility criteria and treatment regimens have been
described previously.1,2 Patients provided informed con-
sent. This was an open-label, randomised, multicenter,phase III trial comparing FOLFIRI plus cetuximab with
FOLFIRI alone. Patients were treated until disease
progression or the occurrence of unacceptable toxicity.
The study was carried out in accordance with the decla-
ration of Helsinki (October 1996).
The primary objective was to examine diﬀerences in
PFS between the treatment groups. The focus of the
present analysis was an assessment of QoL, a secondary
objective from the CRYSTAL study.2.2. Assessments
Radiological response was assessed every 8 weeks by
an independent review committee (IRC) until disease
progression or patient withdrawal. Follow-up evalua-
tions were performed every 3 months. Response was
based on the assessment of best overall response by
the IRC, as described previously.2 Toxicity was graded
according to the National Cancer Institute Common
Toxicity Criteria, version 2.0.2.3. QoL assessments
The European Organization for Research and Treat-
ment of Cancer quality of life questionnaire-core 30
(EORTC QLQ-C30 [version 3.0])13 was used to assess
QoL. Attention was paid to the impact of cetuximab
on social functioning and global health status (GHS)/
QoL.
The QLQ-C30 is a cancer speciﬁc self-administered
core questionnaire of 15 multi-item or single-item scales
derived from the initial 30 questions: ﬁve functional
scales (physical functioning, role functioning, emotional
functioning, cognitive functioning, social functioning);
three symptom scales (fatigue, nausea and vomiting,
pain); six symptom single-item scales (dyspnoea, insom-
nia, appetite loss, constipation, diarrhoea, ﬁnancial dif-
ﬁculties) and one GHS/QoL scale.
Scores were derived from mutually exclusive sets of
items, with scale scores ranging from 0 to 100 after linear
transformation. Higher scores for the functioning and
GHS/QoL scales indicated a higher level of functioning
and a better QoL respectively, whereas higher scores in
symptom scales represented a higher level of symptom.
QoL was assessed at randomisation, every 8 weeks
before the beginning of the next treatment cycle, and
at ﬁnal tumour assessment. Assessment of EORTC
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tionnaire per patient within the QoL assessment time
window was analysed (detailed in the Supplementary
Material).2.4. Statistical considerations
Analysis was performed in the KRAS wild-type
evaluable for QLQ-C30 population comprising patients
from the CRYSTAL intention to treat (ITT) population
with KRAS wild-type tumours who had at least one
evaluable QLQ-C30 questionnaire. All statistical tests
were performed two-sided at the 5% level. No adjust-
ments for multiple comparisons were made.
The null hypothesis to be tested for treatment eﬀect
on QoL was that there was no diﬀerence between the
treatment groups.
The primary analysis was a pattern-mixture analysis
for the GHS/QoL and social functioning which included
a dropout pattern for each treatment group.14 A logistic
regression model, including age, gender, Eastern Coop-
erative Oncology Group performance status (ECOG
PS), number of involved disease sites and liver metasta-
ses as covariables, was used to test if the dropout process
was ‘missing completely at random’ (SAS Proc Logis-
tic). The signiﬁcance of QoL scores on dropout were
assessed using the Wald-test.
QoL data were analysed using descriptive statistics
for multi-item scales and single-item measures for each
treatment group at each QoL assessment time point.
Least-squares (LS) mean estimates for a treatment by
time interaction, and the diﬀerence in the LS means
and associated P values were obtained from an analysis
of variance (ANOVA) model including covariables and
a treatment by time interaction. ANOVA was used for
time points where at least 20% of patients completing
a baseline questionnaire remained in the population.
Diﬀerences between treatment groups were assessed
using the Wilcoxon non-parametric test.
Exploratory analyses included change from baseline
in GHS/QoL and social functioning scores by severity
of skin reactions (none versus any grade or none versus
grade I versus grade II–IV). A Cochran Mantel–Haens-
zel non-parametric test was used to compare diﬀerences
between groups. The change in reported symptoms from
baseline according to tumour response and treatment
was investigated. Eight single-item symptom questions
from the QLQ-C30 questionnaire, considered relevant
to mCRC, were included, covering the symptoms: dysp-
noea, pain, fatigue, appetite loss, constipation and diar-
rhoea. Each item contained four response categories (not
at all; a little; quite a bit; very much). Response catego-
ries were dichotomised using the following algorithm:
patients at baseline were considered symptomatic if they
answered ‘quite a bit’ or ‘very much’ to at least one of theeight single-item symptom questions and asymptomatic
if they answered ‘not at all’ or ‘a little’ to all of the symp-
toms questions. Analysis was performed for treatment
groups on the change in symptoms in patients considered
symptomatic or asymptomatic at baseline. Fisher Exact
test was used to examine the association between symp-
tomatic status at baseline and response, and between
response and treatment group stratiﬁed by symptomatic
status at baseline.
Survival curves and probabilities were estimated
using the Kaplan–Meier method.15 The importance of
symptomatic status at baseline as a prognostic factor
on survival was tested using the Cox proportional haz-
ards regression model with stratiﬁcation for treatment
arm, with signiﬁcance assessed using the Wald-test.3. Results
3.1. Patients, QoL evaluation and compliance
From the CRYSTAL ITT population (n = 1198), 666
patients were KRAS wild-type and 627 of these com-
pleted at least one evaluable QLQ-C30 questionnaire.
Of these patients 48% received FOLFIRI plus cetux-
imab and completed 1333 questionnaires, and 52%
received FOLFIRI and completed 1369 questionnaires.
The proportion of evaluable questionnaires in each
treatment group was 80% and 76% respectively. Compli-
ance rates with questionnaire completion by planned
QoL assessment times deteriorated over time, but were
similar between the treatment arms (Table 1).
Patient baseline characteristics between the CRYS-
TAL ITT and KRAS wild-type QLQ-C30 populations
were not markedly diﬀerent (Table 2).3.2. QoL analysis
For all QLQ-C30 multi-item scales across the assess-
ment time points, only the LS mean scores for nausea
and vomiting at week 16 were signiﬁcantly diﬀerent in
the FOLFIRI versus the FOLFIRI plus cetuximab
arm (14.25 versus 9.08, P = 0.0014). The LS means esti-
mates for the GHS/QoL and social functioning scales
were comparable between the treatment arms, remain-
ing stable across the assessment time points (Fig. 1).
For worst post-baseline scores, for multi-item scales,
only nausea and vomiting was signiﬁcantly diﬀerent
being higher in the FOLFIRI than the combination
arm (20.07 versus 15.93, P = 0.032) (Supplementary
Table S1). For single-item scales, a worse change from
baseline score for dyspnoea in the FOLFIRI plus cetux-
imab arm compared with the FOLFIRI arm (P = 0.020)
was the only signiﬁcant ﬁnding, which also reﬂected the
higher incidence of dyspnoea in the combined group
(10% versus 5%).
Table 1
Analysis of compliance for European Organization for Research and Treatment of Cancer quality of life questionnaire-core 30 (EORTC QLQ-
C30) questionnaires by protocol planned assessment.
Assessment time FOLFIRI FOLFIRI + cetuximab
N1 N2 Compliance rate (N1/N2) (%) N1 N2 Compliance rate (N1/N2) (%)
Baseline 327 246 75 300 225 75
Week 8 317 235 74 292 231 79
Week 16 274 190 69 256 174 68
Week 24 236 155 66 231 154 67
Week 32 174 99 57 191 98 51
Week 40 115 64 56 138 84 61
Week 48 53 28 53 81 49 60
Week 56 28 13 46 42 24 57
Week 64 10 7 70 19 12 63
Final 327 114 35 300 90 30
Note: N1 is the number of patients at the quality of life (QoL) assessment time and N2 is the number of patients with at least one evaluable
questionnaire.
Table 2
Patient and disease characteristics at baseline in the CRYSTAL intention to treat (ITT) and KRAS wild-type quality of life questionnaire-core 30
(QLQ-C30) populations.
ITT population KRAS wild-type quality of life (QoL)
FOLFIRI n = 599 FOLFIRI + cetuximab n = 599 FOLFIRI n = 327 FOLFIRI + cetuximab n = 300
Sex
Male 356 (59) 369 (62) 202 (62) 190 (63)
Female 243 (41) 230 (38) 125 (38) 110 (37)
Age
Median 61 61 59 60
Range 19–84 22–82 19–84 24–80
Eastern Cooperative Oncology Group performance status (ECOG PS)
0 318 (53) 330 (55) 186 (57) 177 (59)
1 260 (43) 248 (41) 128 (39) 112 (37)
2 21 (4) 21 (4) 13 (4) 11 (4)
Number of sites
62 500 (83) 516 (86) 276 (84) 264 (88)
>2 91 (15) 75 (13) 45 (14) 30 (10)
Missing 8 (1) 8 (1) 6 (2) 6 (2)
Liver metastases only
Yes 134 (22) 121 (20) 68 (21) 68 (23)
No 465 (78) 478 (80) 259 (79) 232 (77)
Data are n (%).
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Missing data did not occur at random (further details
in Supplementary Material and Supplementary Fig. S1).
Pattern-mixture analysis demonstrated no signiﬁcant
diﬀerences between the treatment arms for GHS/QoL
(P = 0.12) and social functioning scores (P = 0.43) when
accounting for diﬀerent patient dropout patterns
(Supplementary Table S2).3.4. Sensitivity analysis
Wei–Lachin tests for multi-item scales conﬁrmed no
signiﬁcant diﬀerences between the treatment arms at
any assessment time point or overall (Supplementary
Table S3).3.5. Early skin reactions and QoL
In patients receiving FOLFIRI plus cetuximab, the
mean change from baseline in GHS/QoL was 3.00 in
patients without early skin reactions (week 8) compared
with 1.09 and 0.51 in those with grade I and grade
II–IV early skin reactions, respectively. Social function-
ing score worsened in patients with no skin reactions
(mean 6.41) compared with a slight improvement in
those with grade I (mean 1.64) and grade II–IV (mean
1.48) early skin reactions, respectively. Diﬀerences were
not statistically signiﬁcant (Supplementary Table S4).3.6. Patient symptoms and tumour response
In 471 evaluable patients, the tumour response rate
was signiﬁcantly higher in those who were asymptomatic
FOLFIRI + cetuximab
FOLFIRI
95% CI for difference in treatment groups
100
60
90
80
70
50
40
30
20
10
0
-10
-20
Baseline Week 8 Week 16 Week 24 Week 32 Week 40
Visit
G
SH
/Q
oL
Number of patients
FOLFIRI
FOLFIRI + cetuximab
242 226 185 146 95 61
214 227 168 149 96 82
FOLFIRI
FOLFIRI + cetuximab
95% CI for difference in treatment groups
100
60
90
80
70
50
40
30
20
10
0
-10
-20
Baseline Week 8 Week 16 Week 24 Week 32 Week 40
Number of patients
FOLFIRI
FOLFIRI + cetuximab
241 228 186 148 95 61
215 226 172 151 96 83
Visit
So
ci
al
 F
un
ct
io
ni
ng
A
B
Fig. 1. Least-squares (LS) means scores of European Organization for Research and Treatment of Cancer quality of life questionnaire-core 30
(EORTC QLQ-C30) multi-item scales over time in each treatment group. (A) Global health status/quality of life (GHS/QoL) and (B) social
functioning.
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40% [78/193], P = 0.0002) and remained higher in
asymptomatic (versus symptomatic) patients at baselinein both those receiving FOLFIRI plus cetuximab (65%
[88/136] versus 52% [46/89]) and FOLFIRI alone (52%
[74/142] versus 31% [32/104]). However the addition of
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signiﬁcantly improved response rates in both asymptom-
atic (65% versus 52%, P = 0.0388) and symptomatic
patients at baseline (52% versus 31%, P = 0.0034)
respectively.
For patients who were symptomatic at baseline, in
each treatment group, and at each assessment time
point, generally more became asymptomatic if they
exhibited a tumour response compared with those with
unresponsive tumours (Table 3). Furthermore, symp-
toms were less frequently reported in responders than
in non-responders (Fig. 2) Maximum symptom relief
was reported earlier for patients receiving FOLFIRI
plus cetuximab than with FOLFIRI alone (8 versus
16 weeks). In asymptomatic patients at baseline, more
remained asymptomatic whose tumours responded,
than those whose did not.
3.7. Patient symptoms and survival
Survival was signiﬁcantly longer in patients asymp-
tomatic at baseline compared with those who were
symptomatic at baseline (Fig. 3, median survival 25.7
versus 16.4 months, HR 1.68, P < 0.0001).
4. Discussion
Analysis of the CRYSTAL study data demonstrated
that whilst adding cetuximab to FOLFIRI did not
improve overall QoL in this setting, neither was a nega-
tive impact on QoL observed from this treatment com-
bination. The analysis focused primarily on the
EORTC QLQ-C30 GHS/QoL and social functioning
scales, the latter was considered important due to the
possible inﬂuence that cetuximab-related skin reactions
might have on this scale.1,2 Further a large popula-
tion-based study comparing long-term QoL issues
between CRC patients and the general population
reported social functioning as the most impaired scale.16
Few signiﬁcant diﬀerences in QoL scores were identi-
ﬁed between the treatment arms. Nausea and vomiting
scores at speciﬁc assessment time points, and for the
worst post-baseline score, were signiﬁcantly higher in
the FOLFIRI than the combined treatment arm. In
contrast, a signiﬁcantly worse shift from baseline in sin-
gle-item dyspnoea was reported in the FOLFIRI plus
cetuximab than the chemotherapy alone arm. However,
simple analyses including best and worst score summary
measures do not account for patient dropout patterns
and may be subject to bias. Patient compliance to
QoL questionnaire completion deteriorated over time
but was generally similar between the treatment arms.
Patient dropout was prevalent and missing data did
not occur at random, and was signiﬁcantly associated
with QoL scores. Patients with low QoL scores at base-
line or at the previous assessment time points tended todropout earlier. Pattern mixture analysis, taking into
account missing data and patient dropout patterns,
showed no signiﬁcant diﬀerences in GHS/QoL and
social functioning scores between the treatment arms,
conﬁrming the robustness of the data. Similar ﬁndings
were reported in head and neck cancer12,17 and pre-
treated patients with advanced CRC.6
Further analysis of the CRYSTAL data suggested
that the presence of skin reactions at week 8 did not sig-
niﬁcantly impact the QoL of patients treated with cetux-
imab. Surprisingly, the social functioning score
worsened in patients with no skin reactions compared
with those with early skin reactions. This may have
occurred by chance partly due to the small number of
patients who had no skin reactions with a change from
baseline score.
In heavily pretreated patients with KRAS wild-type
advanced CRC,6 cetuximab reportedly provided a signif-
icant improvement in GHS/QoL score at 8 weeks com-
pared with best supportive care (3.2 versus 7.7, P =
0.02). Furthermore improvements in patient QoL scores
were signiﬁcantly more common in patients whose
tumours showed disease response or disease control com-
pared with disease progression. This was further investi-
gated in the ﬁrst-line setting through additional analysis
of the CRYSTAL data set. Tumour response was signif-
icantly higher in patients who were asymptomatic com-
pared with those who were symptomatic at baseline.
Furthermore patients symptomatic at baseline experi-
enced more symptom relief if their tumour responded
than if it did not. Whilst the association between tumour
response and symptom relief appeared to be independent
of treatment, adding cetuximab to FOLFIRI was associ-
ated with signiﬁcantly higher tumour response, irrespec-
tive of patient baseline symptomatic status, and further
enhanced and accelerated symptom relief from baseline
in patients whose tumours had responded, compared
with those who received FOLFIRI alone.
In advanced CRC patients treated with ﬁrst-line che-
motherapy, baseline social functioning score (assessed
by EORTC QLQ-C30) in multivariate analysis was
reported to be an independent prognostic factor for sur-
vival (HR 0.991, 95% conﬁdence interval (95% CI)
0.987–0.996, P < 0.001).9 These data supported earlier
ﬁndings that baseline overall QoL scale (using the
EORTC QLQ-C30) independently predicted survival
and was a more eﬀective prognostic indicator than per-
formance status.8 In the present study patient survival
was signiﬁcantly longer in asymptomatic patients than
those exhibiting symptoms at baseline. Thus, patient
symptom status at baseline in this setting may be a
potential prognostic indicator for both response and
survival. To date the mechanism underlying the associa-
tion between patient baseline QoL and prognosis is
unknown.9 Studies reporting similar ﬁndings have
suggested that this might reﬂect the patient’s early
Table 3
Change in patient symptoms from baseline according to tumour response and treatment.
Patient status All treated FOLFIRI FOLFIRI + cetuximab
Responders (R) Non-responders (NR) R NR R NR
Symptomatic at baseline 78 (100) 115 (100) 32 (100) 72 (100) 46 (100) 43 (100)
Week 8
Asymptomatic 29 (37) 13 (11) 8 (25) 10 (14) 21 (46) 3 (7)
Symptomatic 39 (50) 58 (50) 19 (59) 32 (44) 20 (43) 26 (60)
Missing 10 (13) 44 (38) 5 (16) 30 (42) 5 (11) 14 (33)
Week 16
Asymptomatic 36 (46) 17 (15) 15 (47) 11 (15) 21 (46) 6 (14)
Symptomatic 28 (36) 28 (24) 11 (35) 18 (25) 17 (37) 10 (23)
Missing 14 (18) 70 (61) 6 (18) 43 (60) 8 (17) 27 (63)
Week 24
Asymptomatic 29 (37) 12 (10) 12 (38) 9 (12) 17 (37) 3 (7)
Symptomatic 26 (33) 13 (11) 12 (38) 10 (14) 14 (30) 3 (7)
Missing 23 (29) 90 (78) 8 (25) 53 (74) 15 (33) 37 (86)
Asymptomatic at baseline 162 (100) 116 (100) 74 (100) 68 (100) 88 (100) 48 (100)
Week 8
Asymptomatic 101 (62) 59 (51) 47 (64) 35 (51) 54 (61) 24 (50)
Symptomatic 33 (20) 19 (16) 15 (20) 12 (18) 18 (21) 7 (15)
Missing 28 (17) 38 (33) 12 (16) 21 (31) 16 (18) 17 (35)
Week 16
Asymptomatic 88 (54) 42 (36) 39 (53) 31 (46) 49 (56) 11 (23)
Symptomatic 20 (12) 14 (12) 7 (9) 7 (10) 13 (15) 7 (15)
Missing 54 (33) 60 (52) 28 (38) 30 (44) 26 (30) 30 (62)
Week 24
Asymptomatic 88 (54) 34 (29) 40 (54) 23 (34) 48 (55) 11 (23)
Symptomatic 27 (17) 8 (7) 11 (15) 7 (10) 16 (18) 1 (2)
Missing 47 (29) 74 (64) 23 (31) 38 (56) 24 (27) 36 (75)
Data shown are n (%).
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baseline QoL scores may correlate with other prognostic
factors such as tumour site and biology, although
limited patient numbers precluded such analysis in the
current study.
To our knowledge this is the ﬁrst analysis of mCRC
patients dichotomised by symptomatic status at base-
line. The post hoc nature of this analysis, and the small
number of patients examined in some subgroups,
require that the data are viewed as hypothesis generat-
ing. Additional studies are needed to further investigate
these relationships to better understand the impact of
tumour response on patients’ perceived QoL, and the
importance of the presence of disease symptoms at base-
line in patient treatment decisions.
It might be expected that the improved eﬃcacy asso-
ciated with adding cetuximab to FOLFIRI in the
CRYSTAL study should be associated with improved
GHS/QoL and social functioning in these patients.
The observation that no such association was found is
likely to be due to a combination of factors. In addition
to the current study, several major studies reporting an
improvement in clinical outcome from the addition of
a biologically-targeted agent (EGFR or VEGF mono-
clonal antibody) to standard ﬁrst-line chemotherapy in
the treatment of mCRC patients, failed to observecorrespondingly marked improvements in QoL com-
pared with the control arm.20–23 In contrast improve-
ments in QoL have been reported in studies
investigating the use of these agents in later lines of
treatment.6,7,24,25 In the current study it may be that
the additional cetuximab-related toxicities negate the
incremental positive eﬀect on patient QoL obtained
from the enhanced tumour shrinkage and slowing of
tumour progression from the treatment combination.
Furthermore as patients receiving ﬁrst-line chemother-
apy report relatively high QoL scores, the capacity to
further improve QoL might be somewhat limited in this
setting in contrast with those studies reporting on later
treatment lines. Indeed in the present study the highest
eﬃcacy was observed in patients asymptomatic at
baseline where further improvement in QoL is diﬃcult
to achieve. Although notably, patients symptomatic
at baseline demonstrated improvements in tumour
response with accompanying marked symptom relief.
In summary, in the CRYSTAL study, the addition of
cetuximab to ﬁrst-line FOLFIRI signiﬁcantly improved
clinical outcome in patients with KRAS wild-type
mCRC without either improving or negatively impact-
ing on GHS/QoL and social functioning. Adding cetux-
imab to FOLFIRI was associated with signiﬁcantly
higher tumour response in patients with or without
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symptom relief in those whose tumours had responded.
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